ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

ClinicalTrials.gov ID: NCT03112603

Public ClinicalTrials.gov record NCT03112603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)

Study identification

NCT ID
NCT03112603
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Incyte Corporation
Industry
Enrollment
330 participants

Conditions and interventions

Interventions

  • Extracorporeal photopheresis (ECP) Drug
  • Ibrutinib Drug
  • Imatinib Drug
  • Infliximab Drug
  • Low-dose methotrexate (MTX) Drug
  • Mycophenolate mofetil (MMF) Drug
  • Pentostatin Drug
  • Rituximab Drug
  • Ruxolitinib Drug
  • mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 28, 2017
Primary completion
May 7, 2020
Completion
Dec 14, 2022
Last update posted
Aug 11, 2025

2017 – 2022

United States locations

U.S. sites
38
U.S. states
21
U.S. cities
31
Facility City State ZIP Site status
Incyte Investigative Site Tucson Arizona 85724
Incyte Investigative Site Duarte California 31010
Incyte Investigative Site La Jolla California 92093-0987
Incyte Investigative Site Los Angeles California 90033
Incyte Investigative Site New Haven Connecticut 06510
Incyte Investigative Site Wilmington Delaware 19803
Incyte Investigative Site Gainesville Florida 32610
Incyte Investigative Site Tampa Florida 33612
Incyte Investigative Site Chicago Illinois 60611
Incyte Investigative Site Chicago Illinois 60612
Incyte Investigative Site Chicago Illinois 60637
Incyte Investigative Site Maywood Illinois 60153
Incyte Investigative Site Indianapolis Indiana 46237
Incyte Investigative Site Westwood Kansas 66205
Incyte Investigative Site Lexington Kentucky 40536
Incyte Investigative Site Boston Massachusetts 02114
Incyte Investigative Site Boston Massachusetts 02215
Incyte Investigative Site Omaha Nebraska 68198-7680
Incyte Investigative Site Hackensack New Jersey 07601
Incyte Investigative Site New York New York 10021
Incyte Investigative Site New York New York 10032
Incyte Investigative Site New York New York 11040
Incyte Investigative Site Chapel Hill North Carolina 27599
Incyte Investigative Site Durham North Carolina 27710
Incyte Investigative Site Winston-Salem North Carolina 27157
Incyte Investigative Site Cincinnati Ohio 45242
Incyte Investigative Site Cleveland Ohio 44106-5048
Incyte Investigative Site Cleveland Ohio 44195
Incyte Investigative Site Columbus Ohio 43210
Incyte Investigative Site Oklahoma City Oklahoma 73104
Incyte Investigative Site Philadelphia Pennsylvania 19104
Incyte Investigative Site Pittsburgh Pennsylvania 15224
Incyte Investigative Site Pittsburgh Pennsylvania 15232
Incyte Investigative Site Nashville Tennessee 37232
Incyte Investigative Site Dallas Texas 75390
Incyte Investigative Site Houston Texas 77030
Incyte Investigative Site Seattle Washington 98109
Incyte Investigative Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 153 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03112603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2025 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03112603 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →